= Emerging. More than 5 years before clinical availability. (26.62%)
= Expected to be clinically available in 1 to 4 years. (38.91%)
= Clinically available now. (34.47%)
MSACL 2020 US : Muddiman

MSACL 2020 US Abstract

Topic: Imaging

Podium Presentation in Room 4 on Thursday at 13:35 (Chair: Christopher Anderton / Wojciech Michno)

New Directions for IR-MALDESI Mass Spectrometry Imaging: From Cells and Bones to Drift Tube Ion Mobility

David Muddiman (Presenter)
North Carolina State University

Presenter Bio(s): David C. Muddiman is the Jacob and Betty Belin Distinguished Professor of Chemistry and Director, Molecular Education, Technology, and Research Innovation Center (METRIC) at North Carolina State University in Raleigh, NC. Prior to moving his research group to North Carolina State University in 2006, David was a Professor of Biochemistry and Molecular Biology and Founder and Director of the Proteomics Research Center at the Mayo Clinic College of Medicine in Rochester, MN. Prior to this appointment, David was an Associate Professor of Chemistry at Virginia Commonwealth University. It was there that he began his professional career as an assistant professor with an adjunct appointment in the Department of Biochemistry and Molecular Biophysics and as a member of the Massey Cancer Center in 1997. These academic appointments followed a postdoctoral fellowship at Pacific Northwest National Lab

Authors: David C. Muddiman and Erin S. Baker
North Carolina State University



The mass spectrometry imaging field is moving into the realm of clinical analysis and this is largely based on MALDI and DESI ionization methods. We have developed a novel ionization method called Infrared Matrix Assisted Laser Desorption Electrospray Ionization (IR-MALDESI) which can be readily adaptable to many different sample types.


Demonstrate the effectiveness of IR-MALDESI for a wide-variety of pre-clinical applications and new directions using different mass spectrometry platform technologies.


A home-built IR-MALDESI sources has been coupled to high resolution accurate mass (Orbitrap) and drift tube ion mobility time-of-flight mass spectrometers. A diverse array of sample types will be presented from HTS/HCS, bones and diverse array of tissues.


For HTS/HCS screening applications, zero sample preparation is required from very complex mixtures with the throughput of 2 samples per second. For bones, we developed a method that does not require decalcification prior to imaging which is critical because HCl will degrade/alter molecular information present in the sample. Finally, a wide range of ongoing studies will be presented including anti-malaria medications, HIV drugs and their co-localization with viral RNA and immune cells, how a fetus responds to exposure to fire retardants.


IR-MALDESI has demonstrated to be extraordinarily adaptable to different sample types and requires no sample preparation. This has allowed us to carry out mass spectrometry imaging for a wide-range of applications that relate to human health and exposure.

Financial Disclosure

Board MemberyesUS-HUPO Executive Committee
IP Royaltyno

Planning to mention or discuss specific products or technology of the company(ies) listed above: